Collaborations To Make a Complex Ecosystem Easy to Navigate
To succeed, it is essential that innovators and researchers take advantage of the support and expertise provided by the innovation ecosystem. However, at times, it could be difficult to navigate the large range of public and private actors throughout the system.
Easy-Access Routes
CCRM Nordic collaborates with relevant actors in the ATMP ecosystem, offering an easy-access route to both expertise and infrastructure.
- Collaborations with innovation hubs such as Testa Center and NorthX.
- Active member of initiatives such as ATMP Sweden and CAMP.
- Links to global networks and expertise.
- Active, established connections with private and public actors.
Collaborations in Practice
-
Analytical Services
Our collaboration with Precision BioAnalytics
Precision BioAnalytics is not only a partner in Analytical Services but also CCRM Nordic’s first investment. Being pioneers in advanced molecular analysis services, they’re expanding CCRM Nordic’s offering beyond current analytical services. Together, we provide proprietary methods and validated technologies that enable exceptional measuring sensitivity and precision.
-
Building expertise
Our collaboration with AdBIOPRO
We’re working with AdBIOPRO to tap into their platform of cutting-edge technologies and dynamic interations with industry and academia. Togheter, we’re focusing on developing innovative manufacturing technologies and competence in advanced bioprocessing to strengthen the competitive advantage of the Nordic region for commercial success of novel ATMPs.
-
Strategic collaboration
Our collaboration with SCT Bio
SCTbio holds extensive expertise in cGMP manufacturing of ATMPs. Where collaborating with SCTbio to bridge the gap until we have our own GMP manufacturing facility up and running in Q2 2026. We’re working together to enable CCRM Nordic’s customers to obtain end-to-end support in their ATMP development and manufacturing.
-
Work force development
CCRM Nordic is taking part in a regional initiative backed by 26.7 MSEK in funding
The EU-funded initiative comprises two subprojects, where one aims to enhance skills across diverse healthcare professional groups and will prepare over 500 healthcare workers – including doctors, nurses, pharmacists, biologists, laboratory scientists – for the transformative changes brought by new gene-, cell-, and tissue-based therapies.
The other subproject is led by CCRM Nordic and focuses on improving access to the right skills for entrepreneurs and small and medium-sized enterprises (SMEs), as well as strengthening cross-sector collaboration. The project runs until early 2028 and includes establishing a new knowledge, training and collaboration center named SCALE. The vision is for the center to continue operating after project close-out and to support the ATMP field on a national level.
The project partners are Sahlgrenska Science Park, the University of Gothenburg, Chalmers University of Technology, Sahlgrenska University Hospital, and CCRM Nordic. Funding is provided by the Environmental and Regional Development Committee of Region Västra Götaland, in collaboration with the European Union through the Swedish European Social Fund Council and the European Regional Development Fund (via Tillväxtverket, the Swedish Agency for Economic and Regional Growth).
Want to collaborate with us?
“Early access to manufacturing capabilities is a main translational driver to bring advanced therapies to the clinic for the benefit of patients. Given Swedish strengths in this area, as well as the potential of cell and gene therapies to address today’s unmet medical needs, we are truly supportive of the report’s findings regarding the need for increased manufacturing capacity for such therapies.”
Johan Hyllner
Executive Director Cell Therapy, External Ecosystem and Innovation, BioPharmaceuticals R&D, AstraZeneca.
CCRM Nordic Consortium Members
We are proud to collaborate with a wide spectrum of innovators and industry leaders, each contributing unique strengths. From AstraZeneca’s global reach to the state of the art equipment of Cytiva.